The Global Benign Prostatic Hyperplasia Therapeutics Market size is expected to reach $7.4 billion by 2027, rising at a market growth of 4.6% CAGR during the forecast period.
Benign prostatic hyperplasia (BPH) is a benign swelling of the prostate gland that is not malignant. Benign prostatic hypertrophy or benign prostatic blockages are terms used to describe this ailment. One of the most common conditions in males over the age of 50 is prostate cancer. The hyperplastic alterations in the prostate tissue that result in prostatic enlargement generate BPH symptoms.
The size of men's prostate grows larger as they grow older. As the prostate gland grows larger, it presses against and compresses the urethra and causes thickening of the bladder’s line. The obstruction increases urine outflow resistance and inhibits detrusor muscle responsiveness as a result of the obstruction. This disorder causes difficulty starting to urinate, a weak urine stream, inability to clear the urinary bladder, and increased pee frequency, which is most noticeable at night.
In men under the age of 40, signs and symptoms of prostate gland enlargement are uncommon. By the age of 60, around a third of men have moderate to severe symptoms, and by the age of 80, approximately half of men have them. Genetic background, diabetes as well as cardiovascular disease, and lifestyle are some factors that are responsible for the occurrence of benign prostate hyperplasia.
Moreover, the expiration of patents on major branded products has resulted in the development of various generic drugs, as well as collaboration among key players for the development of new BPH therapeutics for improved drug efficacy and safe therapy for prevailing drugs as well as impending new molecular entities, all of which contribute to the market's growth. The industry has been fueled further by a significant increase in healthcare expenditures around the world.
The COVID-19 pandemic caused severe losses to the world in terms of economy as well as healthcare. The pandemic caused a significant number of deaths as well as industrial closure. In addition, the COVID-19 outbreak also resulted in a negative influence on the market for treatments for benign prostatic hyperplasia. A significant number of hospitals and clinics around the world have been reconfigured to boost hospital capacity for COVID-19 patients. However, now that COVID-19 vaccines are accessible, several governments are trying to guarantee that life-saving medications and vaccines are supplied without interruption.
Elective procedures of benign pathology were recommended to be postponed until the burden on the healthcare system from COVID-19 lessened because hospitals is expected to encounter a tremendous demand for resources to combat a likely increase in COVID-19 patients. Surgical operations such as TURP, HoLEP, ThuLEP, and PVP have to be postponed as a result.
The inconvenience that is caused by benign prostate hyperplasia keeps increasing as the age of a man increases. In addition, the immunity of aged people is comparatively much lower than young people which make them more vulnerable toward hormonal disorders. BPH is hormonally dependent on testosterone and dihydrotestosterone (DHT) production and is considered a typical aspect of male aging. By the age of 60, approximately half of men have histopathologic BPH, and by the age of 85, 90% of men have it.
With the increasing advancement and modernization, the lifestyle of people across the world is also evolving. The number of people that live a sedentary lifestyle is substantially increasing. The adoption of this lifestyle is likely to cause a significant rise in the number of people with obesity. Moreover, obesity is a major cause that facilitates the occurrence of benign prostatic hyperplasia. Due to the increased pressure on the abdominal area while seating, the prostate of a man undergoes extreme pressure and blockage in the blood vessels. This routine of people causes prostate enlargement or benign prostate hyperplasia.
While both medicines and surgery can be used to treat BPH, both have severe side effects. 5-ARIs (5-alpha reductase inhibitors), Alpha-blockers, and other medication groups are routinely used to treat BPH. Orthostatic hypotension, dizziness, retrograde ejaculation, and rhinitis are all side effects of alpha-blockers. Some of these effects are more common in the elderly people, and they can lead to serious complications such as nausea, vomiting, and diarrhea.
Based on the Therapy, the Benign prostatic hyperplasia therapeutic market is bifurcated into Mono drug therapy and Combination drug therapy. In 2020, the combination therapy recorded a substantial revenue share of the benign prostatic hyperplasia therapeutics market. The increased growth of this segment is attributed to multiple factors such as a wider range of antibiotics, colistin monotherapy having lesser effectiveness than beta-lactam monotherapy, and in vitro data demonstrating antibiotic combinations' synergy.
Based on the Therapeutic class, the Benign prostatic hyperplasia therapeutic market is segmented into Alpha blockers, 5- alpha reductase inhibitors, Phosphodiesterase-5 inhibitors, and Others. In 2020, the 5- Alpha Reductase Inhibitors segment procured a substantial revenue share of the benign prostatic hyperplasia therapeutics market. Only men with confirmed prostate enlargement should use 5-alpha reductase inhibitors. 5-alpha-reductase inhibitors are a class of medications that are used to treat benign prostatic hyperplasia (enlarged prostate) and male pattern hair loss.
Based on the Region, the benign prostatic hyperplasia therapeutic market is analyzed across North America, Europe, APAC, LAMEA. In 2020, North America accounted for the largest revenue share of the benign prostatic hyperplasia therapeutics market. The increased growth of the market across this region is attributed to the robust healthcare infrastructure of the countries across the region. Countries like the US, Mexico, and Canada comprise established healthcare facilities. Moreover, the increased focus of the people toward their health is another major reason for the growth of the market across North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Astellas Pharma, Inc., Eli Lilly and Company, Allergan PLC (AbbVie), Merck Group (Merck Sharp & Dohme Corp.), Boehringer Ingelheim International GmbH, Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Pfizer, Inc., and Abbott Laboratories.
By Therapy
By Therapeutics Class
Benign prostatic hyperplasia (BPH) is a benign swelling of the prostate gland that is not malignant. Benign prostatic hypertrophy or benign prostatic blockages are terms used to describe this ailment. One of the most common conditions in males over the age of 50 is prostate cancer. The hyperplastic alterations in the prostate tissue that result in prostatic enlargement generate BPH symptoms.
The size of men's prostate grows larger as they grow older. As the prostate gland grows larger, it presses against and compresses the urethra and causes thickening of the bladder’s line. The obstruction increases urine outflow resistance and inhibits detrusor muscle responsiveness as a result of the obstruction. This disorder causes difficulty starting to urinate, a weak urine stream, inability to clear the urinary bladder, and increased pee frequency, which is most noticeable at night.
In men under the age of 40, signs and symptoms of prostate gland enlargement are uncommon. By the age of 60, around a third of men have moderate to severe symptoms, and by the age of 80, approximately half of men have them. Genetic background, diabetes as well as cardiovascular disease, and lifestyle are some factors that are responsible for the occurrence of benign prostate hyperplasia.
Moreover, the expiration of patents on major branded products has resulted in the development of various generic drugs, as well as collaboration among key players for the development of new BPH therapeutics for improved drug efficacy and safe therapy for prevailing drugs as well as impending new molecular entities, all of which contribute to the market's growth. The industry has been fueled further by a significant increase in healthcare expenditures around the world.
COVID-19 Impact Analysis
The COVID-19 pandemic caused severe losses to the world in terms of economy as well as healthcare. The pandemic caused a significant number of deaths as well as industrial closure. In addition, the COVID-19 outbreak also resulted in a negative influence on the market for treatments for benign prostatic hyperplasia. A significant number of hospitals and clinics around the world have been reconfigured to boost hospital capacity for COVID-19 patients. However, now that COVID-19 vaccines are accessible, several governments are trying to guarantee that life-saving medications and vaccines are supplied without interruption.
Elective procedures of benign pathology were recommended to be postponed until the burden on the healthcare system from COVID-19 lessened because hospitals is expected to encounter a tremendous demand for resources to combat a likely increase in COVID-19 patients. Surgical operations such as TURP, HoLEP, ThuLEP, and PVP have to be postponed as a result.
Market Growth Factors:
Increasing prevalence of geriatric population
The inconvenience that is caused by benign prostate hyperplasia keeps increasing as the age of a man increases. In addition, the immunity of aged people is comparatively much lower than young people which make them more vulnerable toward hormonal disorders. BPH is hormonally dependent on testosterone and dihydrotestosterone (DHT) production and is considered a typical aspect of male aging. By the age of 60, approximately half of men have histopathologic BPH, and by the age of 85, 90% of men have it.
The evolving lifestyle of people across the world
With the increasing advancement and modernization, the lifestyle of people across the world is also evolving. The number of people that live a sedentary lifestyle is substantially increasing. The adoption of this lifestyle is likely to cause a significant rise in the number of people with obesity. Moreover, obesity is a major cause that facilitates the occurrence of benign prostatic hyperplasia. Due to the increased pressure on the abdominal area while seating, the prostate of a man undergoes extreme pressure and blockage in the blood vessels. This routine of people causes prostate enlargement or benign prostate hyperplasia.
Marketing Restraining Factor:
Side-effects post BPH medications
While both medicines and surgery can be used to treat BPH, both have severe side effects. 5-ARIs (5-alpha reductase inhibitors), Alpha-blockers, and other medication groups are routinely used to treat BPH. Orthostatic hypotension, dizziness, retrograde ejaculation, and rhinitis are all side effects of alpha-blockers. Some of these effects are more common in the elderly people, and they can lead to serious complications such as nausea, vomiting, and diarrhea.
Therapy Outlook
Based on the Therapy, the Benign prostatic hyperplasia therapeutic market is bifurcated into Mono drug therapy and Combination drug therapy. In 2020, the combination therapy recorded a substantial revenue share of the benign prostatic hyperplasia therapeutics market. The increased growth of this segment is attributed to multiple factors such as a wider range of antibiotics, colistin monotherapy having lesser effectiveness than beta-lactam monotherapy, and in vitro data demonstrating antibiotic combinations' synergy.
Therapeutics Class Outlook
Based on the Therapeutic class, the Benign prostatic hyperplasia therapeutic market is segmented into Alpha blockers, 5- alpha reductase inhibitors, Phosphodiesterase-5 inhibitors, and Others. In 2020, the 5- Alpha Reductase Inhibitors segment procured a substantial revenue share of the benign prostatic hyperplasia therapeutics market. Only men with confirmed prostate enlargement should use 5-alpha reductase inhibitors. 5-alpha-reductase inhibitors are a class of medications that are used to treat benign prostatic hyperplasia (enlarged prostate) and male pattern hair loss.
Regional Outlook
Based on the Region, the benign prostatic hyperplasia therapeutic market is analyzed across North America, Europe, APAC, LAMEA. In 2020, North America accounted for the largest revenue share of the benign prostatic hyperplasia therapeutics market. The increased growth of the market across this region is attributed to the robust healthcare infrastructure of the countries across the region. Countries like the US, Mexico, and Canada comprise established healthcare facilities. Moreover, the increased focus of the people toward their health is another major reason for the growth of the market across North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Astellas Pharma, Inc., Eli Lilly and Company, Allergan PLC (AbbVie), Merck Group (Merck Sharp & Dohme Corp.), Boehringer Ingelheim International GmbH, Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Pfizer, Inc., and Abbott Laboratories.
Scope of the Study
Market Segments Covered in the Report:
By Therapy
- Mono Drug Therapy
- Combination Drug Therapy
By Therapeutics Class
- Alpha Blockers
- 5- alpha Reductase Inhibitors
- Phosphodiesterase-5 Inhibitors
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- GlaxoSmithKline PLC (GSK)
- Astellas Pharma, Inc.
- Eli Lilly and Company
- Allergan PLC (AbbVie)
- Merck Group (Merck Sharp & Dohme Corp.)
- Boehringer Ingelheim International GmbH
- Teva Pharmaceuticals Industries Ltd.
- Sanofi S.A.
- Pfizer, Inc.
- Abbott Laboratories
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Global Benign Prostatic Hyperplasia Therapeutics Market by Therapy
Chapter 4. Global Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
Chapter 5. Global Benign Prostatic Hyperplasia Therapeutics Market by Region
Chapter 6. Company Profiles
Companies Mentioned
- GlaxoSmithKline PLC (GSK)
- Astellas Pharma, Inc.
- Eli Lilly and Company
- Allergan PLC (AbbVie)
- Merck Group (Merck Sharp & Dohme Corp.)
- Boehringer Ingelheim International GmbH
- Teva Pharmaceuticals Industries Ltd.
- Sanofi S.A.
- Pfizer, Inc.
- Abbott Laboratories
Methodology
LOADING...
